- Home
- YMAB
as 04-18-2025 1:45pm EST
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 218.4M | IPO Year: | 2018 |
| Target Price: | $18.73 | AVG Volume (30 days): | 318.1K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.86 - $17.78 | Next Earning Date: | 05-06-2025 |
| Revenue: | $87,685,000 | Revenue Growth: | 3.38% |
| Revenue Growth (this year): | -2.83% | Revenue Growth (next year): | 21.10% |
Stock Insider Trading Activity of Y-mAbs Therapeutics Inc. (YMAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gad Thomas | YMAB | CHIEF BUSINESS OFFICER | Mar 7 '25 | Sell | $5.23 | 10,810 | $56,536.30 | 202,721 | |
| Rossi Michael J | YMAB | PRESIDENT & CEO | Mar 7 '25 | Sell | $5.20 | 3,917 | $20,368.40 | 137,083 |
Latest Y-mAbs Therapeutics Inc. News
YMAB Breaking Stock News: Dive into YMAB Ticker-Specific Updates for Smart Investing
MT Newswires
24 days ago
Top Premarket Decliners
Simply Wall St.
a month ago
Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates
MT Newswires
a month ago
Oppenheimer Adjusts Y-mAbs Therapeutics Price Target to $21 From $23, Maintains Outperform Rating
MT Newswires
a month ago
Truist Cuts Price Target on Y-mAbs Therapeutics to $18 From $21, Keeps Buy Rating
GuruFocus.com
a month ago
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ...
Thomson Reuters StreetEvents
a month ago
Q4 2024 Y-mAbs Therapeutics Inc Earnings Call
MT Newswires
2 months ago
Wedbush Cuts Price Target on Y-mAbs Therapeutics to $21 From $23, Keeps Outperform Rating
Simply Wall St.
2 months ago
Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago
Compare YMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "YMAB Y-mAbs Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.